9MIH

273-4D01 Fab in complex with HIV-1 BG505 SOSIP Env trimer and RM20A3 Fab

9MIH の概要

• エントリーDOI: 10.2210/pdb9mih/pdb
• EMDBエントリー: 48290
• 分子名称: 273-4D01 kappa chain Fv, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (11 entities in total)
• 機能のキーワード: hiv-1, sosip, germline targeting, vrc01, clinical trial, precursor antibody, viral protein
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 14
• 化学式量合計: 344852.64

構造登録者

Phulera, S.,Ozorowski, G.,Ward, A.B. (登録日: 2024-12-12, 公開日: 2025-05-21, 最終更新日: 2025-08-13)

主引用文献

Caniels, T.G.,Prabhakaran, M.,Ozorowski, G.,MacPhee, K.J.,Wu, W.,van der Straten, K.,Agrawal, S.,Derking, R.,Reiss, E.I.M.M.,Millard, K.,Turroja, M.,Desrosiers, A.,Bethony, J.,Malkin, E.,Liesdek, M.H.,van der Veen, A.,Klouwens, M.,Snitselaar, J.L.,Bouhuijs, J.H.,Bronson, R.,Jean-Baptiste, J.,Gajjala, S.,Rikhtegaran Tehrani, Z.,Benner, A.,Ramaswami, M.,Duff, M.O.,Liu, Y.W.,Sato, A.H.,Kim, J.Y.,Baken, I.J.L.,Mendes Silva, C.,Bijl, T.P.L.,van Rijswijk, J.,Burger, J.A.,Cupo, A.,Yasmeen, A.,Phulera, S.,Lee, W.H.,Randall Jr., K.N.,Zhang, S.,Corcoran, M.M.,Regadas, I.,Sullivan, A.C.,Brown, D.M.,Bohl, J.A.,Greene, K.M.,Gao, H.,Yates, N.L.,Sawant, S.,Prins, J.M.,Kootstra, N.A.,Kaminsky, S.M.,Barin, B.,Rahaman, F.,Meller, M.,Philiponis, V.,Laufer, D.S.,Lombardo, A.,Mwoga, L.,Shotorbani, S.,Holman, D.,Koup, R.A.,Klasse, P.J.,Karlsson Hedestam, G.B.,Tomaras, G.D.,van Gils, M.J.,Montefiori, D.C.,McDermott, A.B.,Hyrien, O.,Moore, J.P.,Wilson, I.A.,Ward, A.B.,Diemert, D.J.,de Bree, G.J.,Andrews, S.F.,Caskey, M.,Sanders, R.W.
Precise targeting of HIV broadly neutralizing antibody precursors in humans.
Science, 389:eadv5572-eadv5572, 2025

PubMed Abstract: A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01, induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, which target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.

PubMed: 40373114
DOI: 10.1126/science.adv5572

実験手法

ELECTRON MICROSCOPY (3.9 Å)